ASCO GU 2025

What's the role of Enzalutamide in radioligand therapy?

Combining ARPi with PARPi - discussing final OS of…

ARPI for which patients?

Testosterone Recovery after ADT and OS

Darolutamide + ADT reduces risk of progression or death…

Hypo-gonadism bad for survival?

Who benefits most from ARPIs?

Improved Survival with Enzalutamide + Lutetium

Testosterone Recovery

MDT in OMPC

Mevrometostat + Enza: New option for mCRPC

Final OS analyses

Darolutamide + ADT and Doetaxel improves survivas in…

OS in the TALAPRO-2 trial

Local radiotherapy of oligoprogressive mCRPC

Final OS data for TALA + Enza

Durvalumab in UTUC

Phase 2 Mevrometostat

Fish-oil supplement for pts on active surveillance

Mevrometostat - a new EZH2 inhibitor in mCRPC

ENZA-p showed OS benefit and improvement in QoL…

Radical Prostatectomy VS RT in HRPC

Hangi hastalarda ADT+ARPI

Oligometastatik PCa da MDT

Enza+Lu ile artmis sagkalim

Yuksek risk PCa da RP vs RT

Testosteron Geri Gelisi ve Sagkalim

Triplet combination in RCC - there's no free lunch with…

Exciting new substances - but don't over-estimate phase…

KIM-1 - The most interesting biomarker for RCC?

Prognostic and predictive biomarkers in mRCC: Looking…

Advanced Renal Cell Cancer: Adding more drugs does not…

Firstline Update Kidney Cancer

KIM-1 in CheckMate 214

Casdatifan in refracting RCC

Proactive coaching of patients with TKI +/- IO therapy

New data nccRCC

AVION trial at mRCC

New agents / new mode of actions

Cáncer de células renales avanzado: añadir más fármacos…

ADC + ICI - The future for MIBC?

Reassuring data on established ADCs and new insights in…

Exploratory analyses of pCR in NIAGARA: who benefits…

Neoadjuvant chemo-immunotherapy in UTUC: new evidence…

The role of ctDNA in bladder cancer

EV-Pembro continues to be the standard for mTCC

Nivo adjuvant in MIBC - a new standard

Preliminary results of neoadjuvant chemoimmunotherapy…

New FGFR3 inhibitor

Sacituzumab Tirumotecan shows promising antitumor…

Neoadjuvant treatment for UTUC

Durvalumab + Platinum-based chemotherapy shows…

A possible new standard for mUC

HER2 - new marker for bladder preservation

Bladder-sparing approaches - are we there yet?

Promising combination for perioperative setting

ASCO GU 25 - Summary: Urothelial Cancer

New drugs in mUC: The active field of ADCs

Updates neo/adjuvant therapy in MIBC

Phase 2 Mevrometastat

Nuevos fármacos en mUC: El campo activo de las ADCs

ASCO GU 25 - Περίληψη: Ουροθηλιακός καρκίνος

Testicular cancer: Reinventing the wheel

Metastatik seminomda Primer RPLND